Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

70 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Effect of Alirocumab Added to High-Intensity Statin on Platelet Reactivity and Noncoding RNAs in Patients with AMI: A Substudy of the PACMAN-AMI Trial.
Ueki Y, Häner JD, Losdat S, Gargiulo G, Shibutani H, Bär S, Otsuka T, Kavaliauskaite R, Mitter VR, Temperli F, Spirk D, Stortecky S, Siontis GCM, Valgimigli M, Windecker S, Gutmann C, Koskinas KC, Mayr M, Räber L. Ueki Y, et al. Among authors: spirk d. Thromb Haemost. 2024 Jun;124(6):517-527. doi: 10.1055/a-2156-7872. Epub 2023 Aug 18. Thromb Haemost. 2024. PMID: 37595625 Clinical Trial.
Enoxaparin for outpatients with COVID-19: 90-day results from the randomised, open-label, parallel-group, multinational, phase III OVID trial.
Voci D, Götschi A, Held U, Bingisser R, Colucci G, Duerschmied D, Fumagalli RM, Gerber B, Hasse B, Keller DI, Konstantinides SV, Mach F, Rampini SK, Righini M, Robert-Ebadi H, Rosemann T, Roth-Zetzsche S, Sebastian T, Simon NR, Spirk D, Stortecky S, Vaisnora L, Kucher N, Barco S; OVID investigators. Voci D, et al. Among authors: spirk d. Thromb Res. 2023 Jan;221:157-163. doi: 10.1016/j.thromres.2022.10.021. Epub 2022 Nov 12. Thromb Res. 2023. PMID: 36396519 Free PMC article. Clinical Trial.
Impact of alirocumab on plaque regression and haemodynamics of non-culprit arteries in patients with acute myocardial infarction: a prespecified substudy of the PACMAN-AMI trial.
Bär S, Kavaliauskaite R, Otsuka T, Ueki Y, Häner JD, Siontis GCM, Stortecky S, Shibutani H, Temperli F, Kaiser C, Iglesias JF, Jan van Geuns R, Daemen J, Spirk D, Engstrøm T, Lang I, Windecker S, Koskinas KC, Losdat S, Räber L. Bär S, et al. Among authors: spirk d. EuroIntervention. 2023 Jul 17;19(4):e286-e296. doi: 10.4244/EIJ-D-23-00201. EuroIntervention. 2023. PMID: 37341586 Free PMC article. Clinical Trial.
Concomitant Coronary Atheroma Regression and Stabilization in Response to Lipid-Lowering Therapy.
Biccirè FG, Häner J, Losdat S, Ueki Y, Shibutani H, Otsuka T, Kakizaki R, Hofbauer TM, van Geuns RJ, Stortecky S, Siontis GCM, Bär S, Lønborg J, Heg D, Kaiser C, Spirk D, Daemen J, Iglesias JF, Windecker S, Engstrøm T, Lang I, Koskinas KC, Räber L. Biccirè FG, et al. Among authors: spirk d. J Am Coll Cardiol. 2023 Oct 31;82(18):1737-1747. doi: 10.1016/j.jacc.2023.08.019. Epub 2023 Aug 26. J Am Coll Cardiol. 2023. PMID: 37640248 Free article.
Enoxaparin for primary thromboprophylaxis in symptomatic outpatients with COVID-19 (OVID): a randomised, open-label, parallel-group, multicentre, phase 3 trial.
Barco S, Voci D, Held U, Sebastian T, Bingisser R, Colucci G, Duerschmied D, Frenk A, Gerber B, Götschi A, Konstantinides SV, Mach F, Robert-Ebadi H, Rosemann T, Simon NR, Spechbach H, Spirk D, Stortecky S, Vaisnora L, Righini M, Kucher N; OVID investigators. Barco S, et al. Among authors: spirk d. Lancet Haematol. 2022 Aug;9(8):e585-e593. doi: 10.1016/S2352-3026(22)00175-2. Epub 2022 Jun 30. Lancet Haematol. 2022. PMID: 35779558 Free PMC article. Clinical Trial.
Association of Lipoprotein(a) With Changes in Coronary Atherosclerosis in Patients Treated With Alirocumab.
Koskinas KC, Häner J, Ueki Y, Otsuka T, Lonborg J, Shibutani H, Kakizaki R, Kaiser C, van Geuns RJ, Ondracek AS, Praz F, Ambühl M, Spirk D, Lanz J, Daemen J, Heg D, Mayr M, Mach F, Windecker S, Engstrøm T, Lang IM, von Eckardstein A, Losdat S, Räber L. Koskinas KC, et al. Among authors: spirk d. Circ Cardiovasc Imaging. 2024 Nov;17(11):e016683. doi: 10.1161/CIRCIMAGING.124.016683. Epub 2024 Nov 19. Circ Cardiovasc Imaging. 2024. PMID: 39561225 Clinical Trial.
Long-term course of ambulatory patients with COVID-19 initially treated with enoxaparin vs no anticoagulation: final analysis of the OVID (enoxaparin for outpatients with COVID-19) randomized trial.
Fumagalli RM, Voci D, Bikdeli B, Bingisser R, Colucci G, Forgo G, Gerardi T, Gerber B, Grigorean A, Klok FA, Righini M, Robert-Ebadi H, Stortecky S, Ulrich S, Wolf S, Wyss D, Hobohm L, Kucher N, Barco S; OVID investigators. Fumagalli RM, et al. Res Pract Thromb Haemost. 2024 Jul 26;8(5):102534. doi: 10.1016/j.rpth.2024.102534. eCollection 2024 Jul. Res Pract Thromb Haemost. 2024. PMID: 39252826 Free PMC article.
Lesion-Level Effects of LDL-C-Lowering Therapy in Patients With Acute Myocardial Infarction: A Post Hoc Analysis of the PACMAN-AMI Trial.
Biccirè FG, Kakizaki R, Koskinas KC, Ueki Y, Häner J, Shibutani H, Lønborg J, Spitzer E, Iglesias JF, Otsuka T, Siontis GCM, Stortecky S, Kaiser C, Ambühl M, Morf L, Ondracek AS, van Geuns RJ, Spirk D, Daemen J, Mach F, Windecker S, Engstrøm T, Lang I, Losdat S, Räber L. Biccirè FG, et al. Among authors: spirk d. JAMA Cardiol. 2024 Sep 2:e243200. doi: 10.1001/jamacardio.2024.3200. Online ahead of print. JAMA Cardiol. 2024. PMID: 39221516
70 results